Hepatic impairment No dose adjustment is required in clients with delicate or reasonable (Youngster-Pugh A or B) hepatic impairment (see part five.2). Exposure to midostaurin and its active metabolite CGP62221 is substantially lower in people with intense hepatic impairment than that in people with regular hepatic functionality (see portion five.AZ